Indivior Share Discussion Threads

[gregmorg] 23/10/2023 07:59

Certainly hope its all behind us now as these episodes had become quite tedious. A long way back but in these stock market conditions I guess it's barely surprising! Seen this malaise many times before but that doesn't make it that much easier.

[youngers] 23/10/2023 07:40

Well that was expensive but great news it’s all closed now

[grupo guitarlumber] 21/8/2023 13:56

Cboe Europe - 09:55:15 2023-08-21 am EDT







1815.00 GBX +3.18%

[steeplejack] 21/8/2023 07:10

Its hard to see a time when Indivior isn't going to be susceptible to litigation from one quarter or another.There's no doubt that the company is becoming highly proficient at handling litigants,practise makes perfect i suppose.

[adrian j boris] 21/8/2023 07:03

Josh White
Sharecast News
21 Aug, 2023 07:32
Indivior settles some suboxone class action claims, Crest Nicholson lowers profit forecasts

London open

The FTSE 100 is expected to open one point lower on Monday, having closed down 0.65% on Friday at 7,262.43.

Stocks to watch

Addiction treatment specialist Indivior announced on Monday that its US division has settled claims made by the end payor class in the Suboxone antitrust litigation. The FTSE 250 company said it expected to pay $30m, which would be deducted from a reserved $188m for the litigation. Meanwhile, Indivior US was preparing for a 30 October trial related to other claims, but remained open to a settlement there as well.

[youngers] 21/8/2023 06:51

2 down 1 to go

[adrian j boris] 21/8/2023 06:12

21 August 2023

FOR IMMEDIATE RELEASE

Indivior Reaches Agreement with End Payor Class

to Resolve Their Antitrust Multi-District Litigation Claims

Richmond, VA, August 21, 2023 - Indivior PLC (LSE/Nasdaq: INDV) , a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL"). The Agreement marks the resolution of the End Payor Claimants' claims against the Company in the MDL. The Agreement is subject to initial approval by the United States District Court for the Eastern District of Pennsylvania (the "Court"), a notice period, participation by an appropriate number of end payors and final approval of the Court.

As part of the Agreement, the Company expects to pay $30 million to the End Payor Claimants. The settlement amount is in line with the current provision of $188 million for the MDL. Once the Agreement is approved and entered by the Court, the final settlement amount will be recorded against the $188 million provision. Payment into an escrow account for the benefit of the End Payor Claimants is expected to be made in September of 2023, and funded from the Company's existing cash balance.

"We remain focused on helping those suffering from substance use disorders and mental illness," said Mark Crossley, Chief Executive Officer. "Resolving these legacy legal matters at the right value helps us further our mission for patients and creates greater certainty for our stakeholders."

As set out in the Company's half year report on July 27, 2023, the Company continues to prepare for trial on October 30, 2023, in relation to the remaining claims of the direct purchaser class while at the same time exploring the possibility of settlement at the right value with this class.

[gregmorg] 27/7/2023 13:38

The webcast covered the potential litigation statement reasonably comfortably I thought with the cloud looking far less dangerous than I first feared.

Still think Cloud needs removing by October before court proceedings start although company has settled all the other 41-42 cases well within its original $290m provision (of which $187.5m provision remains), in fact the 41-42 litigants settled for $102.5m. Hopefully ,the remaining 2 litigants settle within the company's corporate criteria within a timescale and we move on. Momentum on other fronts appears very encouraging. but no idea as to what the US will make of it!

[youngers] 27/7/2023 12:22

US market seeing this better than U.K.

[casholaa] 27/7/2023 12:05

It's the delay in launch and the EPS.

[youngers] 27/7/2023 09:17

They must understand the difference between a provision and a going concern disclosure ;)

[baddeal] 27/7/2023 09:09

Numis raised tp to 2350 fwiw

[youngers] 27/7/2023 08:53

That’s very much a worst case scenario that has a lot of ifs in it. More importantly the base case assumption hasn’t changed with no further provisions booked which show mgmt still expect to exit this all at the previously stated position. Only change is therefore timing with it coming into the period assessed for going concern as I read it. DYOR

[steeplejack] 27/7/2023 08:10

Yes,Greg,litigation is an ever hanging sword of Damocles unfortunately.The market is mesmerised by the sobering comment in today's statement-"However, if Indivior Inc. were found liable in respect of the remaining claims filed by various private plaintiffs alleging violations of civil antitrust laws and other claims relating to the Group's marketing of SUBOXONE Film (the "Antitrust MDL"), if the Plaintiffs were awarded damages, and if the Group were to be unable to significantly reduce the claimed damages at trial or in any subsequent proceeding (and considering treble damages to be awarded under U.S. antitrust laws), then the Group's financial position, results and future cash flows would be materially adversely affected and the amount of damages would exceed the Group's resources to pay. There is a reasonable prospect the timing of any appeal (or any subsequent proceeding) and/or required payment of the damages could now fall within the going concern period.

[gregmorg] 27/7/2023 08:01

I am afraid the market reaction is the never ending litigation issues and the way the company has spelt it out in the notes this time. Nothing has changed according to the company but investors are bound to run from comments such as these.I am dissappointed to see this given I remain a LT holder

[youngers] 27/7/2023 07:42

Share price movement makes no sense. Excellent set of results and upgraded guidance

[adrian j boris] 27/7/2023 07:21

tend to agree jack

was expecting a trend up

[steeplejack] 27/7/2023 07:18

For the greater part,nowadays i find the reaction of the market to reported results near unfathomable.If technical analysis gives some sort of insight,i'm more than grateful.Yesterday on Wall St,Thermo Scientific's results were initially greeted with a near 7% fall.The shares ended higher.

[adrian j boris] 27/7/2023 06:52

will we have a resistance to 1984

[steeplejack] 27/7/2023 06:39

Updated FY 2023 GuidanceThe Group is updating its FY 2023 guidance to primarily reflect 1) increased NR expectations for SUBLOCADE based on the strong H1 2023 performance and expectations for the remainder of the year and 2) increased NR expectations for SUBOXONE Film due to the anticipated delayed timing of an approved fourth generic buprenorphine/naloxone sublingual film entrant to the U.S. market. Guidance continues to assume 1) commercial launch of OPVEE in the fourth quarter and 2) no material change in exchange rates for key currencies compared with FY 2022 average rates, notably USD/GBP and USD/EUR.

[timmy11] 23/6/2023 15:16

actually its held up pretty well, nearly all others shares are massively down

[steeplejack] 23/6/2023 13:41

Interest in the US has all but evaporated.The management must be a bit disappointed.